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Abstract
Background: As a way to determine markers of infection or disease informing disease management, and to reveal
disease-associated immune mechanisms, this study sought to measure antibody and T cell responses against key
lung pathogens and to relate these to patients’ microbial colonization status, exacerbation history and lung
function, in Bronchiectasis (BR) and Chronic Obstructive Pulmonary Disease (COPD).
Methods: One hundred nineteen patients with stable BR, 58 with COPD and 28 healthy volunteers were recruited
and spirometry was performed. Bacterial lysates were used to measure specific antibody responses by ELISA and T
cells by ELIspot. Cytokine secretion by lysate-stimulated T cells was measured by multiplex cytokine assay whilst
activation phenotype was measured by flow cytometry.
Results: Typical colonization profiles were observed in BR and COPD, dominated by P.aeruginosa, H.influenzae, S.
pneumoniae and M.catarrhalis. Colonization frequency was greater in BR, showing association with increased
antibody responses against P.aeruginosa compared to COPD and HV, and with sensitivity of 73% and specificity of
95%. Interferon-gamma T cell responses against P.aeruginosa and S.pneumoniae were reduced in BR and COPD,
whilst reactive T cells in BR had similar markers of homing and senescence compared to healthy volunteers.
Exacerbation frequency in BR was associated with increased antibodies against P. aeruginosa, M.catarrhalis and S.
maltophilia. T cell responses against H.influenzae showed positive correlation with FEV1% (r = 0.201, p = 0.033) and
negative correlation with Bronchiectasis Severity Index (r = − 0.287, p = 0.0035).
Conclusion: Our findings suggest a difference in antibody and T cell immunity in BR, with antibody being a marker
of exposure and disease in BR for P.aeruginosa, M.catarrhalis and H.influenzae, and T cells a marker of reduced
disease for H.influenzae.
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Background
The chronic lung diseases of bronchiectasis (BR) and
chronic obstructive pulmonary disease (COPD) are both
associated with recurrent airway infections. COPD is a
major cause of death globally, with numbers of deaths
rising [1], and BR is underestimated with incidence ris-
ing in the UK by around 6% annually [2]. Whilst they
differ in disease causation, established disease in both is
mainly characterised by repeated or persistent heavy
bacterial colonization of the damaged lower respiratory
tract. Such infection is associated with inflammation,
mucus production, and reduced ciliary action, which
promotes further infection, inflammation and tissue
damage, in a vicious cycle [3]. Studies have suggested
that infection causes disease exacerbation and dimin-
ished lung function, which are often proportional to the
bacterial load and to reduced diversity [4, 5]. More re-
cent findings propose more species-rich lung ecologies
where alterations in specific bacterial populations, dys-
biosis, is at the heart of clinical disease [6, 7]. Pathogenic
bacteria, as determined clinically by microbiological cul-
ture of expectorated sputum, are dominated by organ-
isms specific to these diseases including Pseudomonas
aeruginosa, Haemophilus influenzae, Streptococcus pneu-
moniae and Moraxella catarrhalis [8]. Recent studies
using DNA-sequencing technology reveal more detailed
bacterial ecosystems in the lungs of diseased patients,
but with culture approaches mainly corroborated [9, 10].
P.aeruginosa is considered the major cause of morbidity
(increased exacerbations and reduced lung function) and
mortality in BR [11], particularly during chronic infection
and mucoid characteristics of the bacterium [12], which
may allow evasion of host immunity. Non-typeable strains
of Haemophilus influenzae (NTHi) are frequently found
in BR [13] and are not targeted by current vaccines. Both
pathogens are also common in COPD albeit with a re-
duced frequency of Pseudomonas infections as compared
to BR [14]. Furthermore, less frequent suppurative infec-
tion and sputum production in COPD results in lower de-
tection of pathogenic microbes, implying fewer infections
than BR. Failure to produce sputum for microbiology,
particularly in younger BR patients and in many COPD
patients, as well as intermittent negative cultures, means
that immune biomarkers of disease may provide a useful
adjunct for directing clinical management.
Knowledge of immunity in BR is limited, but studies sug-
gest immune system genes that are involved in presentation
of antigens to CD4+ T cells, such as HLA-DR1 and DQ5,
play a role [15, 16]. Notably, a role for adaptive immune re-
sponses (specific antibodies and T cells) in protection
against P.aeruginosa and H.influenzae, has been demon-
strated in human vaccine trials in cystic fibrosis-related
bronchiectasis [17, 18] and in mouse vaccination models
[19, 20]. Furthermore, the above-mentioned lung pathogens
appear in individuals with defined immunodeficiencies
[21], underlining the role of antibodies and phagocytes in
protection. Whilst healthy individuals are exposed to the
same pathogenic organisms as diseased individuals,
healthy lungs typically have low levels of bacterial species,
reflecting the naso-pharynx [22]. Immune responses
against pathogenic microbes do not cause overt immuno-
pathology in healthy individuals, but may contribute to
disease in colonized patients due to continuous immune
stimulation by the localised high antigen doses, particu-
larly through excessive Th17 responses that promote
neutrophil infiltration [23]. Together with inflammatory
cytokines, neutrophils are abundant in the sputum of BR
patients, and decline after antibiotic treatment [24]. It is
possible that dysfunction of both innate and adaptive im-
munity contribute directly or indirectly to disease in both
BR and COPD. The aim of this study was to characterise
antibody and T cell responses against key lung microbes
in disease-stable patients with BR and COPD, charac-
terised by the Bronchiectasis Severity Index (BSI) and
GOLD guidelines, respectively, in comparison to controls
(healthy volunteers), and to relate the immune responses
to culture-based bacterial colonization, lung function and
frequency of exacerbation.
Methods
Study participants and samples
Ethical approval for the project was granted by the local
NHS Research Ethics Committee, the NRES Committee
North East – County Durham & Tees Valley (ref 12/NE/
0248). Adult patients with (non-CF) BR, COPD and
healthy volunteer (HV) controls, were recruited at the
Freeman Hospital, Newcastle upon Tyne. Female to
male ration was about 1.5:1. BR is routinely confirmed
by high-resolution computed tomography (HCRT), and
COPD according to prevailing GOLD guidelines (BTS
and NICE 2010, [25]). Diverse aetiologies of BR were in-
cluded in the study, with the exception of known
immunodeficiency.
Patients were clinically stable at the time of assess-
ment. They underwent spirometry to determine forced
expiratory volume in 1 s (FEV1), and Forced Vital
Capacity (FVC), from which FEV1% predicted, FEV1/
FVC ratio and FVC % predicted were obtained. The
bronchiectasis severity index (BSI) score, as previously
validated [26], was assessed. Patients were divided into 2
groups: either those with one severe exacerbation requir-
ing hospitalisation or those with 3 or more exacerbations
per year, compared to those not requiring hospitalisation
and having less than 3 exacerbations per year. The exac-
erbations were determined for the preceding 12 months.
Colonization history of patients was also available going
back at least 4 years. Patients were categorised by patho-
gen status based on positive sputum cultures. ‘Chronic
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colonization’ was defined here as 2 positive sputum cul-
tures at least 3 months apart in 12 months. ‘Chronic
currently’ was defined as a positive sputum culture at
time of blood sampling (for immune responses), and
more than 2 positive sputum cultures in 12 months.
‘Previously chronic’ was defined as more than 2 positive
sputum cultures in 12 months > 2 years ago. ‘Occasional’
infection was ≥ 1 positive sputum culture per year. ‘No
colonization’ was sputum culture negative over at last
3 years (Table 3).
Sample processing and bacterial culture
Heparinized venous blood samples from patients and
healthy controls were processed to give plasma for
ELISA and peripheral blood mononuclear cells (PBMC)
for T cell assays (detailed in Additional file 1). Sputum
samples were cultured in the Microbiology Department,
Freeman Hospital, according to national standards.
Enzyme-linked immunosorbent assay (ELISA) for serum
antibody measurement
An indirect enzyme-linked immunosorbent assay (ELISA)
method was used: to determine optimal dilutions for the
coating of microbe-derived antigens, for initial serum
screening, and to undertake titration for total IgG (all
subclasses combined) to give an end-point titre (e.g. 1 in
1000), and for the measurement of individual Ig subclasses
(given as absorbance for 1 in 25 dliution), as described
previously [27](see Additional file 1).
T cell responses to microbial antigens
ELIspot as previously optimised and described [28] (see
Additional file 1) was used to measure T cell responses
against a range of stimuli including bacterial lysates plus
selected peptide epitopes where available. For cell activa-
tion and surface staining of cells, PBMC were thawed
and activated with stimuli for 20 h as detailed in the
supplement. Intracellular staining was performed to de-
termine the number and phenotype of IFNγ-producing
or activated CD69+ T cells following stimulation.
Measurement of cytokines in culture supernatants using
multiplex ELISA
Cytokines in supernatants from stimulated PBMCs were
measured using the Mesoscale Scale Discovery (MSD)
multiplex cytokine Kit (Meso Scale Diagnostic, LLC,
Gaithersburg, USA). Multiplex kit – pro-inflammatory
panel 1 (for IL-1β, IL-2, IL-4, IL-6, IL-8, IL-10,
IL-12p70, TNFα) and cytokine panel 2 (IL-17A, IL-5)
were used. See Additional file 1.
Statistics
The immunological data was tested for normal distribu-
tion using the Shapiro-Wilk test. For normally distributed
data t-test and Pearson correlation was used whilst for not
normally distributed data the Mann-Whitney U test and
Spearman’s correlation was used. A priori calculations
based on our previous data suggested that sufficient num-
bers were included to detect a modest effect with 0.9
power to a significance level of 0.05. SPSS v.15 and Graph
Pad Prism were used for analysis. The cut-off value for
statistical significance was p < 0.05.
Results
Clinical data
This study examined antigen-specific immune responses
in 119 BR and 58 COPD patients, and in 28 HV (Table 1),
against lung pathogens that are commonly isolated from
these patient groups. The patient groups showed typical
clinical features, similar to previously-published reports
e.g. average FEV1% predicted, which was 68 for BR, 49 for
COPD and 113 for HV. FVC % predicted and FEV1/FVC
ratio were also reduced in the patient groups compared to
HV. The BR group was predominantly of a post-infection
aetiology, whilst COPD was smoking-related, and all pa-
tients with BR and COPD were in a clinically stable state
with no current exacerbation. At the time of taking the
blood samples, the BR group had a higher proportion of
patients producing sputum (93%) that could be microbio-
logically tested than COPD (66%), and BR patients showed
greater overall populations infected with the main bacter-
ial species (Table 2), many with multiple species. H.influ-
enzae was the most commonly identified species in both
BR and COPD, followed by P.aeruginosa, S.pneumoniae
and M.catarrhalis in BR, and M.catarrhalis, S.pneumoniae
and P.aeruginosa in COPD.
Antibody responses
The first experiments involved ELISA to determine anti-
body levels (total specific IgG), by end-point titre,
against the main bacterial species in BR, COPD and HV.
BR showed significantly higher levels of antibody against
Table 1 Demographics of the subjects included in this study
Characteristics BR
n = 119
COPD
n = 58
HV
n = 28
Sex (no.)
Male/female)
45/74 Not av. Not av.
Age (y) 65 ± 1.08 69 ± 1.23 54 ± 3.01
Exacerbations (per year) 4 ± 0.29 3 ± 0.38 Not app.
Smoking history (pack years) 8 ± 1.33 47 ± 4.08 Not av.
FEV1 (% predicted) 68 ± 2.68 49 ± 2.70 113 ± 2.83
FVC (% predicted) 82 ± 2.48 77 ± 2.40 118 ± 2.7
FEV1/FVC ratio 66 ± 1.52 50 ± 2.17 83 ± 1.75
Values are presented as means ± SEM, exacerbations represents the number
per year. FEV1 represent forced expiratory volume in the first second and FVC,
forced vital capacity. Not av., indicates the data are not available, whereas Not
app., means that the category was not applicable
Jaat et al. Respiratory Research  (2018) 19:106 Page 3 of 12
P.aeruginosa, H.influenzae and S.maltophilia compared
to HV (Fig. 1a). COPD failed to show significant in-
crease from HV for any of the bacteria. HV only showed
significantly higher antibody responses than BR and
COPD against S.pneumoniae.
The next aim was to relate specific IgG antibody levels
against bacteria, to bacterial colonization status and his-
tory. Because of the relatively low infection rates in COPD,
the numbers were insufficient to determine significance,
and so we focussed on BR. BR patient pathogen status was
analysed and condensed into a categorization shown in
Table 3, indicating ‘current chronic’, ‘previous chronic’, ‘oc-
casional’, or ‘no colonization’. Whilst there was an overall
trend for antibody titre to increase based on colonization
(Fig. 1b), this was only significant for P.aeruginosa and
S.maltophilia. We further studied immunoglobulins by
class and isotype across the disease groups and found in
general higher levels of IgG1 and IgA in BR than COPD
(Fig. 1e-g).
T cell responses
T cell responses, in the form of IFNγ spot-forming cells
per 106 PBMC, were measured against the bacterial anti-
gens as for the antibodies. In contrast to the antibody
responses, there was an overall trend towards the BR
and COPD groups having lower T cell responses than
the HV group (Fig. 1c). BR and COPD both had signifi-
cantly lower responses than HV against P.aeruginosa
and S.pneumoniae. As with the antibody responses, the
relatively low infection rates in COPD meant that there
were insufficient numbers of infected patients to deter-
mine significance and so BR was focussed upon for relat-
ing to colonization (Fig. 1d). Whilst there was an overall
trend for T cell responses against all antigens to
associate with an occasional number of exposures, as
opposed to none or chronic, this was not significant.
Exacerbation and lung function
The contribution of bacterial colonisation, as per Table 3,
to lung function as measured by FEV1% predicted, was ex-
amined in the BR cohort. Overall there was a downward
trend in lung function as bacterial colonisation became
more frequent and with current positive cultures (Fig. 2a),
with P.aeruginosa, M.catarrhalis and S.maltophilia all
showing a significant reduction. The numbers with M.-
catarrhalis and S.maltophilia were low (n = 10 and 9,
respectively) with 52 and 75% of these, respectively, being
co-colonised with P.aeruginosa.
Since exacerbation of disease is a key event in need of
urgent clinical management, and makes up part of the
validated BSI scoring, exacerbation history of the BR
patients was used to determine whether there were any
informative associations with immunological responses.
The patients were compared based on them having less
than 3 exacerbations, greater than or equal to 3, and
those that were hospitalised within the last year. This
breakdown of the patients was first validated by examin-
ing the FEV1% predicted within the groups compared to
HV (Fig. 2b). A significant decrease in lung function was
seen moving from HV, through < 3 exacerbations, ≥ 3
exacerbations, to hospitalised. Since the hospitalised
group comprise a variable causality (and not necessarily
greater disease) and was relatively small in number, this
was omitted from further analysis. Small but statistically
significant increases in IgG titres against P.aeruginosa,
H.influenzae and M.catarrhalis were seen between < 3
and ≥ 3 exacerbations (Fig. 3a-c). For T cell responses no
significant differences were seen between the 2 groups
for any bacterium (Fig. 3d-f ).
T cell phenotypes
Since T cell responses of a single Th type (Th1/IFNγ)
may not be the only response against the lung bacteria,
antigen-specific T cell cytokine responses were also mea-
sured in the supernatants of antigen-stimulated PBMC
by multiplex cytokine analysis (Fig. 4a-h). A sub-group
of BR patients who were good responders to the anti-
gens, determined by both IFNγ ELIspot and by CD69
expression following antigen-stimulation, were selected
for stimulation, as well as similarly good HV responders.
For IFNγ, IL-2 and IL-17 responses the BR patients
showed a trend, though not significant, towards reduced
levels for both P.aeruginosa and H.influenzae compared
to HV. For IL-4, BR patients showed marginally reduced
responses for P.aeruginosa but significantly increased re-
sponses to H.influenzae compared to HV, although the
responses showed considerable variability. Finally, IL-10
responses showed a trend for increased response in BR
Table 2 Microorganisms isolated from the sputum of patients
with BR and COPD
Microorganism Identified Bronchiectasis
patients (%)
Chronic obstructive
pulmonary disease
patients (%)
NT. H.influenzae 63.8 31
P. aeruginosa 56.3 12.0
S. pneumoniae 44.5 17.2
M. catarrhalis 37.8 24.1
A. fumigatus 22.6 3.4
S. maltophilia 15.9 3.4
Candida. sp 14.4 6.9
S aureus 30.3 1.7
E.coli 20.1 5.2
No pathogen isolated 2.5 17.2
No sputum produced 6.8 43.7
BR patients n = 119; COPD patients n = 58
NT = non-typeable
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Fig. 1 Anti-bacterial antibody and T cells responses. Antibody levels against bacterial antigens were measured by ELISA: (a) IgG titres (1/value)
against bacteria in BR, COPD and HV groups; (b) Antibody responses against bacteria were compared based on bacterial colonization. T cell
responses against bacterial antigens were measured by IFNγ ELIspot: (c) IFNγ spot-forming cells per 106 PBMC against bacteria in BR, COPD and
HV groups; (d) IFNγ spot-forming cells per 106 PBMC against bacteria were compared based on bacterial colonization. Anti-pseudomonas Ig
subclasses and IgG isotypes in BR (e), COPD (f) and HV (g) subgroups. Mean value + SEM are given. *p < 0.05, ***p < 0.001. Mann-Whitney tests
were performed
Table 3 Classification of patients based on sputum microbiological results
0 No pathogen isolated (NPI)
1 Occasional ≥ 1 isolation in a year
Chronic colonization is defined by the isolation of bacteria
in sputum culture on 2 or more occasions, 3 months apart, within 1 year
2 Chronic previously Chronic in preceding 5 years but not last 2 years
3 Chronic currently Current, and chronic in last 2 years prior to recruitment
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over HV for both antigens, but again with much variabil-
ity. All other cytokine responses tested were equivocal.
Flow cytometry analysis was used to further character-
ise antigen-responding T cells in the same subgroups of
BR and HV. Similar proportions of activated CD69+
CD4+ T cells were seen in BR and HV following stimula-
tion with P.aeruginosa and H.influenzae, all being
significantly higher than the unstimulated (medium)
control (Fig. 5a). Co-staining of the activated CD4+ T
cells with CD69 and for IFNγ intracellularly showed a
concordance of the two forms of activation but showed
that there were more CD69+ cells than IFNγ+ cells
(Additional file 1). Staining of the CD69+ stimulated
cells for other potentially important markers (see
Additional file 1: Figure S1), showed significant levels of
staining (above isotype controls) on CD4+ CD69+ T cells
(Fig. 5b-e), but no significant difference between BR
patient and HV cells.
When the relationship between T cell responses (IFNγ
ELIspot) and lung function (FEV1% predicted) was
examined, a significant positive correlation (Fig. 6a),
albeit weak (r = 0.201; p = 0.033), was found only with T
cell response against H.influenzae. With removal of the
outlier, significance was still retained (r = 0.186, p = 0.049).
Furthermore, a stronger (negative) correlation was ob-
served between BSI and anti-H.influenzae T cell re-
sponses (Fig. 6c) (r = − 0.287; p = 0.003), and again
significance remained upon removal of an outlier
(r = − 0.265, p = 0.0035). Conversely, a moderate
negative correlation was seen (Fig. 6b) with antibodies
against H.influenzae (r = − 0.224; p = 0.018), but none
with BSI (Fig. 6d). This suggests that T cell responses
are associated with improved lung function and less
severe disease, whereas higher levels of H. influenzae
antibodies are associated with poorer lung function.
Overall, no relationships were evident between the
magnitudes of antibody and T cell responses against
any of the bacteria examined. Furthermore, T cell and
antibody responses against bacteria showed no rela-
tionships with one another (data not shown).
a
b
Fig. 2 Lung function and exacerbation in BR. FEV1% predicted is a measure of lung function. (a) FEV1% predicted in BR patients grouped based
on their bacterial colonization. (b) FEV1% predicted in BR patients based on exacerbation in the last year, and in HV – healthy subjects. Mean
values + SEM are given. Mann-Whitney tests were performed
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Discussion
This study began by comparing immune responses
against common lung pathogens in BR, COPD and HV.
The clinical categorisation of the patients followed
standard processes and was in keeping with other stud-
ies in the field, as were the microbiology results ob-
tained. One expectation was that the degree of exposure
to the microbes will be proportional to the magnitude of
immune response measured. This was broadly the case
for antibody responses, which were higher in BR than
COPD and HV, particularly against P.aeruginosa,
H.influenzae and S.maltophilia, reflecting rates of posi-
tive sputum cultures in BR and COPD. Measurement of
isotype components of the antibody responses against
P.aeruginosa showed a high IgG1 component in BR and
HV, compared to COPD which had a higher IgM. This
may suggest that COPD has reduced isotype switching,
which is usually controlled by cognate T cell responses,
through CD40:CD40L interaction and through cyto-
kines. Reduced or altered antibody responses as we have
seen here could be due to increased regulatory T cells,
as have been demonstrated in COPD, which may depress
protective immunity [29].
Having found specific antibody responses to be in-
creased in BR, the question was whether these responses
showed a direct dynamic relationship with colonization
levels. Sufficient numbers for this analysis were only
available in the BR group. Whilst there was a trend for
increasing antibodies with colonisation for each individual
pathogen, only P.aeurginosa and S.maltophilia showed
significance. We categorised patients based on their
exacerbation frequency (< 3, ≥ 3) which were validated by
a
b
c
d
e
f
Fig. 3 Antibody and T cell responses in BR groups of different recent exacerbation history. Antibody levels against bacterial antigens were measured
by ELISA to give IgG titres (1/value) in BR groups with < 3 compared to > 3 exacerbations in the last 12 months against bacteria. T cell
responses were measured by IFNγ ELIspot and expressed as spot-forming cells per 106 PBMC. (a, d) P.aeruginosa (b, e) M. catarrhalis
(c, f) H.influenzae. Mean values + SEM are given. Mann-Whitney tests were performed
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showing reducing lung function. Although significant,
only modest increases in antibody against P.aeruginosa,
M.catarrhalis and H.influenzae were found in BR with ≥ 3
exacerbations compared to < 3. Antibody response only
against H.influenzae showed a negative correlation with
FEV1% predicted, suggesting it to be a marker of disease
and exposure.
The measurement of T cell responses against lung
pathogens may be useful for the diagnosis of latent
infection, as is the case of the Quantiferon test for
a
b
c
d
e
f
g
h
Fig. 4 Cytokine responses in a subset of BR patients and HV. PBMC from BR and HV were stimulated with bacterial antigens P.aeruginosa (PSA)
and H.influenzae (Hi), and supernatants were tested for the following cytokines: (a) IL-2, (b) IL-4, (c) IL-12, (d) IL-17, (e) IL-2, (f) IL-5, (g) IL-13,
(h) IL-10. Mean values + SEM are given in pg/ml. Mann-Whitney tests were performed
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Mycobacterium tuberculosis (Mtb). In this study T cell
responses showed an overall tendency for reduction in BR
and COPD compared to HV, associated with colonisation
status, with responses to P.aeruginosa and S.pneumoniae
being significantly reduced. This suggests that increased
infection and exposure may exhaust the T cell response.
Within the BR group T cell responses showed a trend for
being highest in the group that had occasional infections,
for all pathogens tested. The highest T cell responses were
found for H.influenzae and M.catarrhalis which coincides
with them having intracellular phases that require T cells
for efficient immune protection or eradication. T cell
a b
c
d
e
Fig. 5 Flow cytometry responses on a subset of BR patients and HV. Flow cytometry was performed on PBMC from BR and HV stimulated with
bacterial antigens. (a) CD69 activation marker following stimulation with medium only, P.aeruginosa or H.influenzae. The % of CD4+ CD69+
activated T cells with phenotypic markers following stimulation with (b) P.aeruginosa, (c) anti-CD3 monoclonal antibody, (d) H.influenzae and
(e) medium only. Mean % values + SEM are given. Mann-Whitney tests were performed
a b
c d
Fig. 6 Lung function and BSI related to immune responses against H.influenzae in BR. (a) T cell responses against H.influenzae measured by IFNγ
ELIspot and expressed as spot-forming cells per 106 PBMC plotted against FEV1% predicted. (b) T cells responses against H.influenzae plotted
against BSI. (c) Antibody levels against H.influenzae were measured by ELISA to give IgG titres (1/value) in BR plotted against FEV1% predicted.
(d) Antibody responses against H.influenzae plotted against BSI. Spearman correlation was performed
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responses did not show any associations with exacerbation
level. However, increased IFNγ ELIspot T cell responses
against H.influenzae showed significant positive associ-
ation, albeit weak, with lung function (FEV1%) and nega-
tive association with BSI, which may suggest that T cells
are protective against disease, in contrast to antibody re-
sponses which showed a negative correlation with FEV1%,
and may simply be associated with more infection. The
next aim was to investigate further the nature of the T
cells reactive against the two major pathogens, P.aerugi-
nosa and H.influenzae, in a sub-group of BR patients who
were good responders to the antigens and in comparison
to good-responding HV. There was a tendency for IFNγ,
IL-2 and IL-17 to be reduced in BR patients compared to
HV, suggesting greater antigen exposure, where memory
T cells producing IL-2 convert to T cells secreting effector
cytokines. Conversely, there was a tendency for IL-10 to
be increased in BR for both antigens suggesting their con-
version to a regulatory (Tr1) phenotype due to high and
sustained antigen exposure at the mucosal surface. IL-4
responses showed a significant increase in BR against
H.influenzae, similar to published work on COPD [30],
but a tendency for the opposite for P.aeruginosa. This sug-
gests a discrepancy in immune responses between BR and
HV, and against the two pathogens, reflecting the fact that
T cell response against H.influenzae was protective against
disease. When pathogen-reactive T cells, based on CD69
and CD4 staining, were examined for further key pheno-
typic markers no differences were found between BR and
HV. All reactive cells had high levels of CD49d, a lung
homing receptor, but low levels of inflammatory homing
receptors and the marker of senescence PD-1.
The measurement of antibodies and T cells specific for
P.aeruginosa and H.influenzae in patients with BR [31,
32] and COPD [30, 33] has previously revealed increased
antibody responses associated with repeated infection,
but decreased T cell responses, despite CD4+ T cell pres-
ence and oligoclonal TcR T cell expansion in the lungs
[34, 35], suggesting immune dysregulation such as T cell
exhaustion. Thus, while immune responses may be
protective, or a marker of infection by microbes, their
dysregulation may be detrimental to the patient due to
reduced protection from infection or through immuno-
pathology as suggested in cystic fibrosis [36]. Studying
responses in disease states is important as this may reveal
mechanisms of disease that are direct (via immunopathol-
ogy) or indirect (via anti-microbial effects) that may pro-
vide therapeutic targets. Furthermore, studies of such
blood-based immunodiagnostics may be useful for diagno-
sis and stratification of patients, and their responses to
treatment [31], when microbiology or genomic analysis is
not possible or reliable (young BR patients, no sputum,
difficult to culture microbes, false negative). Baseline
immunity related to contemporaneous microbiota may
particularly be a useful way to identify a frequent exacer-
bator phenotype. With regard to an antibody marker of
current colonization with P.aeruginosa, this data showed
92% specificity (ability to show true negatives) and 73%
sensitivity (ability to show true positives) based on the HV
mean + 2 sd. This is similar to previous findings [31].
The strengths of the study were the extensive nature
of the immunological investigations carried out on pa-
tients, particularly those with BR, who were well charac-
terised clinically and microbiologically. One weakness is
that numbers of COPD patients producing sputum, and
thus with positive cultures, was too low to allow a suffi-
ciently powered analysis to be undertaken for COPD
and so the study focussed on BR after the initial obser-
vations (Fig.1). Furthermore, it would have been useful
to have longitudinal data of immune responses and
microbiology, and this is the subject of a future study.
Another weakness is that microbiological culture is not
able to determine the complete microbial makeup in a
sample if it contains fastidious unculturable bacteria. We
are currently addressing this by carrying out genomic
analysis of patient sputum samples as well as microbio-
logical culture. Finally, the cytokine secretion data would
have benefited from larger numbers, particularly for HV,
and again this is the subject of ongoing work.
Conclusion
In conclusion, exposure to these lung pathogens generates
antibody responses of magnitudes that are broadly propor-
tional to the level of exposure and thus disease (exacerba-
tion, reduced lung function), and may be useful markers of
disease. T cell responses appear to be reduced in patients
with increased infection rates, and are proportional to lung
function and BSI for H.influenzae, suggesting that they
may be protective against such a pathogen that is partially
intracellular. The T cell responses in patients differ little in
phenotype from HV, apart from possible subtle cytokine
differences that are currently being examined further. The
interaction between T cells and antibody-producing B cells,
and how the two arms of the adaptive immune response
interact and influence innate immunity, and ultimately im-
pact on bacterial infection and disease, is likely to be com-
plex and multifactorial. The data in this study suggests the
use of antibodies for Pseudomonas-inducing disease diag-
nosis, whilst T cells may indicate protective immunity
against Haemophilus, suggesting a possible benefit of T
cell-inducing vaccines.
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